Public market insider buying at Bright Minds Biosciences (DRUG)

Public market insider buying at Bright Minds Biosciences (C:DRUG)

Ian McDonald, a Director, acquired 15,200 Common Shares on a direct ownership basis at prices ranging from $6.400 to $6.850 between March 18th, 2021 and March 23rd, 2021. This represents a $100,875 investment into the company's shares and an account share holdings change of 1.8%.

Bright Minds Biosciences is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Bright Minds Biosciences Inc. is a Canada-based pre-clinical biosciences company. The Company has a portfolio of compounds designed to target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is focused on developing targeted therapies for the treatment of mental health and neurological disorders through the use of serotonergic compounds. Its product pipeline includes Serotonin (5-HT), 5-HT2C, 5-HT2A and 5-HT2A + 5-HT2C.